# Medical Content Audit: Specialty Modules

**Auditor:** PM&R Board Review Content Auditor
**Date:** 2026-04-07
**Files audited:**
- `/Users/zacharyshumaker/Desktop/MY INVENTIONS/P&O Training/lib/data/module_contents/pediatric_po_content.dart`
- `/Users/zacharyshumaker/Desktop/MY INVENTIONS/P&O Training/lib/data/module_contents/special_populations_content.dart`
- `/Users/zacharyshumaker/Desktop/MY INVENTIONS/P&O Training/lib/data/module_contents/materials_fabrication_content.dart`
- `/Users/zacharyshumaker/Desktop/MY INVENTIONS/P&O Training/lib/data/module_contents/advanced_tech_content.dart`

**Reference sources consulted:**
- `reference-text/12-Pediatric-PO.md`
- `reference-text/13-Special-Populations.md`
- `reference-text/11-Materials-Fabrication.md`
- `reference-text/10-Advanced-Technology.md`
- `reference-text/14-Outcomes-Energy-Expenditure.md`

---

## Summary

| File | CRITICAL | MAJOR | MINOR |
|---|---|---|---|
| pediatric_po_content.dart | 0 | 0 | 3 |
| special_populations_content.dart | 0 | 3 | 3 |
| materials_fabrication_content.dart | 0 | 0 | 0 |
| advanced_tech_content.dart | 0 | 0 | 1 |

**Total findings: 10** (0 CRITICAL, 3 MAJOR, 7 MINOR)

No board-relevant facts were outright wrong, but several numeric imprecisions exist in the Special Populations energy-expenditure table, and one clinical vignette in Special Populations contains an internally incoherent premise that should be rewritten.

---

## 1. pediatric_po_content.dart

### Finding 1.1 — MINOR: Checkpoint answer inconsistent with own timeline
- **Location:** line ~223–228 (`CheckpointBlock` in UE Milestones section)
- **Current content:** Question asks when to first fit a child with congenital UE deficiency with a passive prosthesis; correct answer is `"At 3-6 months (when sitting independently)"`.
- **Medically correct / source:** The file's own UE timeline (line 198) and the reference chapter 12.4 both specify **6 months** as the age of independent sitting and first passive UE prosthesis fitting. "3-6 months" is imprecise — independent sitting does not typically occur before ~6 months. The Board Pearl at line 217 also says 6 months explicitly. The checkpoint should read "At approximately 6 months (when sitting independently)."
- **Source:** `reference-text/12-Pediatric-PO.md` lines 154–163; Cuccurullo P&O chapter, UE pediatric fitting milestones.
- **Severity:** MINOR (internal inconsistency; still close to correct developmental window).

### Finding 1.2 — MINOR: Milwaukee brace apex threshold slightly imprecise
- **Location:** lines 643–656 and lines 727–733 (Milwaukee brace card and comparison table)
- **Current content:** `"Indicated for curves with apex ABOVE T8 (high thoracic)"`; comparison table: `"Above T8"`.
- **Medically correct / source:** Reference chapter 12.12 (line 546) specifies **"apex above T7–T8"**. The "above T8" shorthand is widely used but slightly imprecise; most authoritative sources describe the Milwaukee as indicated for curves with apex at **T7 or above** (Boston handles T8 and below). Clinically and for board purposes this is acceptable, but the content should ideally use "T7–T8" phrasing for precision.
- **Source:** `reference-text/12-Pediatric-PO.md` line 546, 602.
- **Severity:** MINOR.

### Finding 1.3 — MINOR: Bracing criteria range inconsistency (25–45° vs 25–40°)
- **Location:** line 573 (`"Cobb angle 25-45 degrees (moderate curves)"`) vs line 580 (`"SRS/AAOS guidelines: brace if Cobb 25-40° and Risser 0-2"`)
- **Current content:** The same card lists two slightly different ranges for the bracing indication. Board Pearl at line 587 then says "25–45°".
- **Medically correct / source:** Standard teaching and the reference chapter 12.11 use **25–40°** as the primary bracing indication, with 40–45° as "bracing may be attempted, approaching surgical threshold." The content file's Cobb angle management table at lines 743–752 correctly reflects this nuance. The bullet points on line 573 and the pearl at line 587 conflating the two ranges is imprecise.
- **Source:** `reference-text/12-Pediatric-PO.md` lines 469–476.
- **Severity:** MINOR.

**No other pediatric errors found.** The ISO/ISPO classification, fibular hemimelia management, PFFD Aitken/Paley classifications, prosthetic fitting milestones, terminal bony overgrowth facts (bone frequency, age cutoff ~12, disarticulation exemption), Pavlik harness efficacy table by age, Ponseti sequence and tenotomy/compliance statistics, Legg-Calvé-Perthes Scottish Rite data, myelomeningocele orthotic level prescriptions, Risser staging, and BrAIST trial numerics (242 patients, 72% vs 48%, NNT=3, >13 hrs/day 90–93%) all match the reference chapter and are correctly presented.

---

## 2. special_populations_content.dart

### Finding 2.1 — MAJOR: Clinically incoherent ABI checkpoint vignette
- **Location:** lines 71–76 (`CheckpointBlock` after TBI section)
- **Current content:**
  > "A diabetic patient with an ABI of 0.5 is being evaluated for BKA wound healing. However, the ABI may be falsely elevated in diabetic patients due to: … Medial arterial calcification (Monckeberg sclerosis)"
- **Medically correct / source:** An ABI of **0.5** is severely reduced (moderate-to-severe PAD per the file's own table at lines 50–51) and is **not** a falsely-elevated reading — false elevation requires ABI **>1.30–1.40**. The question premise contradicts itself: if the patient's ABI is 0.5, it is not falsely elevated, and Monckeberg sclerosis does not explain that reading. The correct pedagogical vignette should use an ABI of e.g., **1.4** or state "the ABI appears normal at 1.2 but clinical exam suggests PAD" before asking about false elevation. As written, this is a board-question integrity problem.
- **Source:** `reference-text/13-Special-Populations.md` lines 49–74 (AHA ABI interpretation).
- **Severity:** MAJOR (testable fact is correct in the answer, but the vignette scaffolding is clinically wrong and could confuse learners).

### Finding 2.2 — MAJOR: Bilateral TT energy expenditure range inflated
- **Location:** lines 374–381 (energy expenditure table)
- **Current content:** `"Bilateral TT", "40-60% increase"`
- **Medically correct / source:** Reference chapter 14.1 (line 45) and chapter 13.7 (line 233) both cite **~41%** increase for bilateral TT (Waters et al. and PLOS ONE 2019 meta-analysis). The 40–60% upper bound is substantially higher than the evidence base. The file's own Bilateral TT comparison card at line 391 correctly uses "~40-60%" but the tab-level bullet description should read approximately **40% (~41%)**.
- **Source:** `reference-text/14-Outcomes-Energy-Expenditure.md` line 45; Waters RL 1976.
- **Severity:** MAJOR (a commonly tested energy-expenditure number; the quoted upper bound is not supported by any primary literature the reference cites).

### Finding 2.3 — MAJOR: Unilateral TF and hip disarticulation energy values low/imprecise
- **Location:** lines 374–381 (energy expenditure table)
- **Current content:**
  - `"Unilateral TF", "50-65% increase"`
  - `"Hip Disarticulation", ">80% increase"`
- **Medically correct / source:** Reference chapter 14.1 (lines 43–47):
  - Unilateral TF (traumatic): **60–70%** increase
  - Unilateral TF (vascular): **65–100%** increase
  - Hip disarticulation: **100–200%** increase
  The file's "50–65%" for unilateral TF is too low (50% is below any cited traumatic-TF value) and "≥80%" for hip disarticulation is also too low — hip disarticulation typically at least doubles baseline energy cost.
- **Source:** `reference-text/14-Outcomes-Energy-Expenditure.md` lines 43–47; Waters RL 1976.
- **Severity:** MAJOR (these are board-tested energy-hierarchy numbers).

### Finding 2.4 — MINOR: ABI interpretation table compresses AHA categories
- **Location:** lines 47–53
- **Current content:** Row `"0.91 – 1.30", "Normal"` (no separate borderline row)
- **Medically correct / source:** Reference chapter 13.2 and the AHA 2012 scientific statement separate **1.00–1.30 Normal** from **0.91–0.99 Borderline / elevated cardiovascular risk**. Grouping 0.91 with "normal" omits the borderline category, which is a frequently-tested nuance. The file's subsequent breakdown of 0.71–0.90 as "Mild" and 0.41–0.70 as "Moderate" also differs from the reference's 0.41–0.90 "Mild to moderate" grouping; both are defensible cuts in the literature but should match the cited reference.
- **Source:** `reference-text/13-Special-Populations.md` lines 49–57.
- **Severity:** MINOR.

### Finding 2.5 — MINOR: ABI false-elevation threshold inconsistency (>1.30 vs >1.40)
- **Location:** line 52 (table row `"> 1.30"`), lines 54–57 (board pearl), and line 64 (`">1.30-1.40"`)
- **Current content:** The file uses 1.30 as the false-elevation threshold in the primary table and board pearl, but the TBI bullet uses "1.30–1.40."
- **Medically correct / source:** The AHA 2012 scientific statement (reference line 57) uses **>1.40** as the formal "non-compressible" threshold; many teaching sources use >1.30 as a practical cutoff. The inconsistency within the file should be resolved — ideally standardize on ">1.40" to match the reference chapter 13.2 table.
- **Source:** `reference-text/13-Special-Populations.md` line 57.
- **Severity:** MINOR.

### Finding 2.6 — MINOR: "Dysvascular amputees die within 5 years ~50%" phrased as "Nearly 50%"
- **Location:** line 31
- **Current content:** `"Nearly 50% of dysvascular amputees die within 5 years of amputation"`
- **Medically correct / source:** Reference chapter 13.1 (line 33) phrases this identically ("Nearly 50%"). This is accurate. NOTE: the prompt asked to verify "50% 5-year mortality" — which matches. Included here only to confirm it was checked and is correct; **no correction needed**.
- **Severity:** Not an error. (Listed for completeness of audit.)

**No other special populations errors found.** The 82% dysvascular statistic, 55% contralateral amputation within 2–3 years, TCC gold-standard numbers (88.9% wound closure, 16% utilization), Eichenholtz staging (0–III), Medicare Therapeutic Shoe Program eligibility and Option A/B coverage, stubbies energy/speed statistics (7–23% reduction, 25% faster), IDEO outcomes (>80% avoid amputation), OEF/OIF RTD rates (16.5% vs 2.3%, TT 22%), TUG amputee cutoffs (8.17 / 9.25 sec), and MMSE/MoCA cognitive screening guidance are all accurately presented and match the reference chapter.

---

## 3. materials_fabrication_content.dart

**Zero errors found.**

Every audited claim matches `reference-text/11-Materials-Fabrication.md`:

- Thermoplastic vs thermoset definitions and reheat behavior (reversible vs irreversible cross-linking)
- Low-temp (150–170°F / 65–77°C) vs high-temp (300–500°F / 150–260°C) thermoplastic working temperatures
- Polypropylene as most commonly used definitive AFO/KAFO/TLSO material
- Thermoset resin examples (acrylic, polyester, epoxy)
- Steel (heaviest, highest UTS, ~7.8 g/cm³), aluminum (~1/3 steel weight, ~2.7 g/cm³), titanium (~45% lighter than steel, best strength-to-weight of any metal)
- Carbon fiber has the highest strength-to-weight ratio of ALL P&O materials; brittle failure mode; energy storage for dynamic response feet
- Fiberglass composition and uses; carbon/glass hybrid applications
- Material science terminology (stress, strain, yield point, UTS, creep, fatigue, stress relaxation, viscoelasticity, ductile vs brittle failure)
- Casting/rectification ("add to load, remove to relieve"); lamination workflow; CAD/CAM; 3D printing current status
- Closed-cell vs open-cell foam moisture absorption distinction (Pelite, Plastazote)

---

## 4. advanced_tech_content.dart

### Finding 4.1 — MINOR: C-Leg falls reduction phrased as "up to 64%" then "approximately 80%"
- **Location:** line 161 (Clinical Benefits card: `"Reduced incidence of falls (up to 64% reduction in uncontrolled falls)"`) vs line 141 (MPK Falls Board Pearl: `"approximately 80% reduction in overall falls"`)
- **Current content:** Two different falls-reduction figures appear (64% and 80%) without clear disambiguation.
- **Medically correct / source:** Reference chapter 10.1.7 (line 130) cites "up to **64–80%** reduction in uncontrolled falls" as the combined-literature range; the 80% figure specifically comes from the C-Leg vs non-MPK retrospective person-years data cited in the same content file's own table at lines 128–137 (178 vs 1,102 falls per 1,000 person-years ≈ 84% reduction). The numbers are not wrong individually, but the "up to 64%" phrasing understates the C-Leg-specific data and can confuse learners. Recommend phrasing as "**64–80% reduction in uncontrolled falls** (C-Leg person-years data ~80–84%)."
- **Source:** `reference-text/10-Advanced-Technology.md` lines 49–59, 130.
- **Severity:** MINOR.

**No other advanced-tech errors found.** Specifically verified as correct:

- C-Leg 50 Hz sampling rate and first MPK (1997)
- Genium alternating stair ascent, OPG mode, gyroscope/accelerometer
- **X3 is IP67-rated** (the file correctly states IP67; the audit prompt's "IP68" claim is inconsistent with the reference chapter, which uses IP67 throughout — the content file matches the reference)
- Rheo Knee MR fluid mechanism; OASIS 1 Plie data (comparable mobility, lower QoL vs C-Leg)
- Medicare K2 MPK expansion **September 2024**; the four K2 coverage criteria; ASCENT K2 trial supporting evidence; L-codes (L5856, L5857, L5858)
- BiOM/Empower: **16% metabolic reduction**, 15% faster self-selected speed; Ottobock ownership since 2018
- OPRA system: **FDA PMA December 2020**, 65 participants, two-stage threaded screw design, ~6-month healing, 92% fixture survival at 5 years, 67% superficial and 22% deep infection rates
- POP system: press-fit, 5% deep infection vs OPRA 22%, zero implant loosening, 77% superficial infections, VA offering OPRA since January 2022
- Dumanian RCT **n=28**, TMR PLP improvement 3.2 vs -0.2 (longitudinal p=0.03)
- TMR transhumeral nerve transfers (musculocutaneous→biceps short head; median→brachialis; distal radial→lateral triceps; ulnar→medial triceps) — correctly listed
- COAPT pattern recognition: 8-subject RCT with TMR transhumeral amputees, SHAP p=0.04, Clothespin p=0.02, **FDA Class II clearance 2017**
- IMES: NCT03644394, 2 subjects, 3-DOF control, investigational only

---

## Auditor's Global Notes

1. **Strong alignment with reference chapters.** All four content files show strong fidelity to the corresponding reference markdown chapters. The reference chapters themselves are already verified (verification-report footers). Discrepancies are limited to a small number of imprecisions and one clinically-incoherent vignette.

2. **Highest-priority fix:** the ABI = 0.5 checkpoint vignette in `special_populations_content.dart` (Finding 2.1). This should be rewritten before the content is released to learners — the current wording is internally contradictory and risks teaching an incorrect clinical inference.

3. **Second-priority fix:** the energy-expenditure table in `special_populations_content.dart` (Findings 2.2, 2.3). These values are board-tested and should match the published Waters et al. / PLOS ONE meta-analysis ranges used in the reference chapter. Update the table to:
   - Unilateral TT (traumatic): 10–25% (vascular 20–40%)
   - Unilateral TF (traumatic): 60–70% (vascular 65–100%)
   - Bilateral TT: ~41%
   - Bilateral TF: >200%
   - Hip disarticulation: 100–200%

4. **No CRITICAL errors identified.** Every finding is either an imprecision, an internal inconsistency, or a pedagogical scaffolding problem — none are outright board-relevant factual errors that would teach learners a wrong answer (except arguably the ABI vignette premise, which is downgraded to MAJOR because the answer option the question rewards is still the correct board fact).

5. **Materials & Fabrication file: fully clean.** No corrections recommended.
